Key Performance
More- Earnings Score: N/A
- Momentum Score: N/A
- True Yield: N/A
- Financial Health Score: N/A
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
Small Chinese Firms Withdraw Wall Street IPO Applications
Three small Chinese companies have formally withdrawn their Nasdaq IPO applications since April, signaling pressure from underwriters amid a regulatory crackdown on suspicious 'pump and dump' listings. The withdrawals reflect increased hostility toward Chinese listings on Wall Street, driven by U.S. political pressure and stricter regulations, with the CSRC approving only two new U.S. listings in the past five months.
05/14/2026, 11:20 AM • Benzinga
Rosen Law Firm is notifying investors about multiple securities class action lawsuits. The primary case involves Navan, Inc., where the firm alleges that offering documents for the October 2025 IPO contained false and misleading information regarding increased sales and marketing expenses. The lead plaintiff deadline is April 24, 2026. Additional lawsuits involve Lufax Holding Ltd and PomDoctor Ltd.
04/12/2026, 11:56 AM • GlobeNewswire
Rosen Law Firm is reminding investors in PomDoctor Ltd., Navan, Inc., and Lufax Holding Ltd. of upcoming lead plaintiff deadlines in securities class action lawsuits. PomDoctor investors have until April 13, 2026 to join the class action, which alleges the company was subject to fraudulent stock promotion schemes, insider share dumping, and misleading statements about business operations.
04/12/2026, 11:27 AM • GlobeNewswire
A class action lawsuit has been filed against PomDoctor, Ltd. (NASDAQ: POM) alleging that company defendants made materially false statements and failed to disclose a fraudulent stock promotion scheme involving social media misinformation, coordinated share dumping by insiders using offshore accounts, and artificial trading activity that inflated stock prices during the class period of October 9, 2025 to December 11, 2025.
04/10/2026, 3:00 PM • GlobeNewswire
Pomerantz Law Firm has filed class action lawsuits against PomDoctor Ltd. for alleged securities fraud involving a 'pump and dump' scheme using social media impersonators. PomDoctor's stock surged from $4.00 to $6.09 before crashing 91% to $0.50 on December 10, 2025. Similar lawsuits have been filed against AMC Entertainment Holdings and NuScale Power Corporation. Investors with losses are urged to contact the firm by the April 6, 2026 deadline to potentially become lead plaintiffs.
04/07/2026, 3:47 PM • GlobeNewswire
A class action lawsuit has been filed against PomDoctor, Ltd. (NASDAQ: POM) in the U.S. District Court for the Southern District of New York. The complaint alleges that the company made materially false statements and failed to disclose a fraudulent stock promotion scheme involving social media misinformation, insider share dumping through offshore accounts, and artificial trading activity that inflated stock prices. Investors who purchased PomDoctor securities between October 9, 2025 and December 11, 2025 have until April 7, 2026 to apply as lead plaintiffs.
04/06/2026, 5:37 PM • GlobeNewswire
Rosen Law Firm reminds investors of PomDoctor Ltd. (NASDAQ: POM) of the April 7, 2026 lead plaintiff deadline for a securities class action lawsuit. The lawsuit alleges that PomDoctor made false statements and failed to disclose a fraudulent stock promotion scheme involving social media misinformation, insider share dumping, and artificial trading activity that inflated stock prices.
04/05/2026, 9:05 AM • GlobeNewswire
Rosen Law Firm reminds investors who purchased PomDoctor Ltd. (NASDAQ: POM) securities between October 9, 2025 and December 11, 2025 of the April 7, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that PomDoctor made false statements and failed to disclose a fraudulent stock promotion scheme involving social media misinformation, insider share dumping through offshore accounts, and artificial trading activity that inflated stock prices.
04/02/2026, 8:02 PM • GlobeNewswire
Rosen Law Firm announces securities class action lawsuits against PomDoctor Ltd. and other companies. PomDoctor investors who purchased shares between October 9, 2025 and December 11, 2025 are encouraged to join the class action before the April 7, 2026 deadline. The lawsuit alleges PomDoctor engaged in fraudulent stock promotion schemes involving social media misinformation, insider share dumping, and misleading public statements about the company's business and prospects.
03/30/2026, 3:53 PM • GlobeNewswire
Rosen Law Firm is notifying investors in PomDoctor Ltd. (NASDAQ: POM) of an April 7, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that PomDoctor made false statements and failed to disclose a fraudulent stock promotion scheme involving social media misinformation, insider share dumping, and artificial trading activity that inflated stock prices.
03/27/2026, 11:01 PM • GlobeNewswire
A class action lawsuit has been filed against PomDoctor, Ltd. in the U.S. District Court for the Southern District of New York on behalf of investors who purchased securities between October 9, 2025 and December 11, 2025. The complaint alleges that defendants made materially false statements and failed to disclose a fraudulent stock promotion scheme involving social media misinformation, insider share dumping through offshore accounts, and artificial trading activity that inflated stock prices.
03/25/2026, 6:33 PM • GlobeNewswire
Beijing And Washington Squeeze Fading Market For Chinese IPOs In US
China's regulatory push to unwind offshore VIE structures and require repatriation of IPO proceeds, combined with U.S. House committee scrutiny of boutique investment banks over pump-and-dump schemes, is effectively ending the market for Chinese IPOs in the U.S. While this may benefit international investors by providing direct claims on underlying Chinese assets, only a handful of well-established Chinese companies are expected to successfully list in the U.S. going forward.
03/25/2026, 8:11 AM • Benzinga
Law firm Holzer & Holzer, LLC announced April 6, 2026 lead plaintiff deadlines for shareholder class action lawsuits against BlackRock TCP Capital Corp., Mereo BioPharma Group plc, POMDOCTOR LIMITED, and Ultragenyx Pharmaceutical Inc., alleging materially false statements and/or failure to disclose material facts. Investors who purchased shares during specified periods and suffered losses are encouraged to seek legal representation.
03/24/2026, 8:00 AM • GlobeNewswire
Rosen Law Firm is notifying investors who purchased PomDoctor Ltd. (NASDAQ: POM) securities between October 9, 2025 and December 11, 2025 of a securities class action lawsuit. The lawsuit alleges that PomDoctor made false statements and failed to disclose a fraudulent stock promotion scheme involving social media misinformation, insider share dumping through offshore accounts, and artificial trading activity that inflated stock prices. The lead plaintiff deadline is April 7, 2026.
03/21/2026, 9:52 AM • GlobeNewswire
A class action lawsuit has been filed against PomDoctor, Ltd. (NASDAQ: POM) alleging that company defendants made materially false statements and failed to disclose a fraudulent stock promotion scheme involving social media misinformation, impersonated financial professionals, and coordinated share dumping by insiders using offshore accounts. Investors who purchased PomDoctor securities between October 9, 2025 and December 11, 2025 are encouraged to join the case, with a lead plaintiff deadline of April 6, 2026.
03/19/2026, 12:00 PM • GlobeNewswire
